View Older Stories View More Recent Stories

Feb 12, 2021 06:20AM Xeris Pharmaceuticals Inc. (XERS) Receives EC Approval of Ogluo Injection for Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
Feb 12, 2021 03:00AM Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With D
Jan 29, 2021 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 5, 2021 04:05PM Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
Dec 31, 2020 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 22, 2020 07:06AM Xeris Pharmaceuticals (XERS) Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke in Israel and the Palestinian Authority
Dec 22, 2020 07:00AM Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke® in Israel and the Palestinian Authority
Dec 11, 2020 04:00AM Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2
Nov 27, 2020 01:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 9, 2020 07:00AM Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
Nov 2, 2020 07:00AM Xeris Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
Oct 30, 2020 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 21, 2020 09:27AM Pre-Open Stock Movers 10/21: (ASTC) (SNAP) (CALX) Higher; (GSX) (NAVI) (NFLX) Lower (more...)
Oct 20, 2020 05:33PM After-Hours Stock Movers 10/20: (ASTC) (SNAP) (PRTA) Higher; (NAVI) (NFLX) (APTX) Lower (more...)
Oct 20, 2020 04:07PM Xeris Pharmaceuticals Inc. (XERS) Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection
Oct 20, 2020 04:05PM Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection
Oct 2, 2020 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 8, 2020 08:00AM Xeris Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Aug 28, 2020 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 20, 2020 04:15PM Xeris Pharmaceuticals Inc. (XERS) Appoints John Shannon President and COO
Aug 20, 2020 04:15PM Xeris Pharmaceuticals Appoints John Shannon President and Chief Operating Officer
Aug 10, 2020 07:00AM Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights
Aug 3, 2020 04:05PM Xeris Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
Jul 31, 2020 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 30, 2020 08:18AM Xeris Pharmaceuticals Inc. (XERS) Reports Additional Data from Phase 1b Comparative Study of Novel Concentrated Diazepam Formulation (XP-0863) & Expedited Clinical Path Forward
Jul 30, 2020 08:00AM Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path Forward
Jul 1, 2020 07:00AM Xeris Pharmaceuticals Announces Gvoke HypoPen™ – the First Autoinjector for Severe Hypoglycemia – Now Available
Jun 26, 2020 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 18, 2020 08:03AM Xeris Pharmaceuticals Inc. (XERS) Reports Positive Topline Results from Phase 2 Comparative Study of Novel Pramlintide-insulin Co-formulation in Adults with Type 1 Diabetes Mellitus
Jun 18, 2020 08:00AM Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus
Jun 15, 2020 06:01AM Xeris Pharmaceuticals Inc. (XERS) Reports Positive Results from Outpatient Stage of Ph. 2 Study of Developmental Gvoke (RTU) Micro Glucagon
Jun 15, 2020 06:00AM Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk of Hypoglycemia During a
May 29, 2020 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 22, 2020 08:01AM Xeris Pharmaceuticals (XERS) Announces Positive Findings From Outpatient Portion of Phase 2 Proof-of-Concept Study of Its Developmental RTU Glucagon in Patients at Risk of Postprandial Hypoglycemia Fo
May 22, 2020 08:00AM Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial H
May 14, 2020 03:00AM Xeris Pharmaceuticals Signs Exclusive Agreement With Clinigen to Supply and Distribute Gvoke™ Outside the U.S on a Named Patient Basis
May 7, 2020 07:00AM Xeris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Updates
Apr 30, 2020 08:00AM Xeris Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
Apr 29, 2020 07:00AM Xeris Extends $0 Copay for Gvoke™ PFS For People With Diabetes Through May 31, 2020
Apr 20, 2020 08:02AM Xeris Pharmaceuticals Inc. (XERS) Announces Positive Topline Results From Study of Its Novel Formulation of Diazepam Injection
Apr 20, 2020 08:00AM Xeris Pharmaceuticals Announces Positive Topline Results From a Study of Its Novel Formulation of Diazepam Injection
Mar 27, 2020 05:30PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 26, 2020 04:15PM Xeris Pharmaceuticals Announces $0 Copay for Gvoke™ PFS for People With Diabetes
Mar 19, 2020 08:00AM Xeris Pharmaceuticals Reinforces the Importance of GVOKE™ PFS for People With Diabetes
Mar 11, 2020 06:00AM Xeris Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline Progress
Feb 28, 2020 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 27, 2020 04:05PM Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020
Feb 27, 2020 04:05PM Xeris Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11, 2020
Feb 18, 2020 09:00AM Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
Jan 31, 2020 04:05PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories